Ira Jacobson, MD
Gastroenterology · New York, NYNPI 1851488936
Payments from drug & device makers
Across 563 payments — averaging $3156.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$331K
- E.r. Squibb & Sons, L.L.C.$263K
- Janssen Research & Development, LLC$215K
- GSK$206K
- Intercept Pharmaceuticals, Inc.$134K
- Ipsen Bioscience Inc.$113K
- plus $516K from 28 others
Across 11 payments — averaging $1034.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$6K
- Redhill Biopharma Inc.$5K
- Eli Lilly$728
What the payments were for
- Consulting fees$267,96084%
- Speaking & faculty fees$20,8457%
- Travel & lodging$24,7448%
- Food & beverage$6,8002%
- Education$2390%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 133 | $331,162 |
| E.r. Squibb & Sons, L.L.C. | 18 | $262,750 |
| Janssen Research & Development, LLC | 38 | $215,148 |
| GSK | 69 | $205,932 |
| Intercept Pharmaceuticals, Inc. | 46 | $133,811 |
| Ipsen Bioscience Inc. | 59 | $112,865 |
| Eli Lilly | 34 | $108,930 |
| Madrigal Pharmaceuticals | 43 | $91,526 |
| Merck | 24 | $88,188 |
| Roche TCRC, Inc. | 5 | $59,883 |
| AstraZeneca | 3 | $57,690 |
| Viiv Healthcare Company | 6 | $24,128 |
| Novo Nordisk | 11 | $14,566 |
| Ipsen Pharma SAS | 9 | $10,384 |
| AbbVie | 6 | $9,750 |
| Intercept Pharma Europe Ltd. | 3 | $8,695 |
| Biomarin Pharmaceutical Inc. | 2 | $7,650 |
| Siemens Medical Solutions USA, Inc. | 5 | $7,308 |
| Modernatx, Inc. | 1 | $5,025 |
| Genentech USA, Inc. | 2 | $4,570 |
| F. Hoffmann-la Roche AG | 5 | $4,388 |
| Novo Nordisk AS | 1 | $3,500 |
| Alnylam Pharmaceuticals Inc. | 3 | $2,834 |
| Kowa Research Institute, Inc. | 4 | $2,660 |
| Janssen Global Services, LLC | 2 | $1,737 |
| Novartis | 1 | $1,050 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $257 |
| Echosens North America, Inc. | 1 | $201 |
| Ipsen Biopharmaceuticals, Inc | 5 | $163 |
| Orphalan Inc | 5 | $134 |
| Shionogi Inc | 1 | $117 |
| Mirum Pharmaceuticals, Inc. | 1 | $100 |
| Mallinckrodt Hospital Products Inc. | 4 | $96 |
| Intra-sana Laboratories | 2 | $58 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,777,256 in reported general payments places this provider in the 95th percentile of 1,682 gastroenterology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Carvedilol | 26 | $173 |
| Prednisone | 14 | $162 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in New York
- David HudesmanNew York$3.6M
- Ellen ScherlNew York$2.9M
- Bruce SandsNew York$2.8M
- Arun SwaminathNew York$2.7M
- Sonal KumarNew York$2.3M
- David Carr LockeNew York$2.1M
- Arthur KornbluthNew York$1.9M
- James MarionNew York$1.7M
- Jean Frederick ColombelNew York$1.6M
- Scott FriedmanNew York$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.